These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 28836106

  • 1. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.
    Youland RS, Kreofsky CR, Schomas DA, Brown PD, Buckner JC, Laack NN.
    J Neurooncol; 2017 Dec; 135(3):535-543. PubMed ID: 28836106
    [Abstract] [Full Text] [Related]

  • 2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K.
    Acta Neuropathol Commun; 2020 Nov 23; 8(1):201. PubMed ID: 33228806
    [Abstract] [Full Text] [Related]

  • 3. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y.
    Oncotarget; 2015 Sep 22; 6(28):24871-83. PubMed ID: 26314843
    [Abstract] [Full Text] [Related]

  • 4. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J, Yan L, Ai P, He Y, Guan H, Wei Z, He L, Mu X, Liu Y, Peng X.
    Neurosurg Rev; 2021 Jun 22; 44(3):1447-1455. PubMed ID: 32529528
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM.
    Neuro Oncol; 2017 Feb 01; 19(2):242-251. PubMed ID: 27571885
    [Abstract] [Full Text] [Related]

  • 6. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.
    J Neurooncol; 2017 Nov 01; 135(2):273-284. PubMed ID: 28884377
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
    Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A.
    J Clin Oncol; 2020 Oct 10; 38(29):3407-3417. PubMed ID: 32706640
    [Abstract] [Full Text] [Related]

  • 8. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.
    Mod Pathol; 2015 Feb 10; 28(2):177-86. PubMed ID: 25081751
    [Abstract] [Full Text] [Related]

  • 9. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
    Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, Iseki H, Tamura M, Saito T, Okamoto S, Chernov M, Hayashi M, Okada Y.
    Neurosurg Focus; 2015 Jan 10; 38(1):E7. PubMed ID: 25599276
    [Abstract] [Full Text] [Related]

  • 10. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.
    J Neurooncol; 2015 Sep 10; 124(2):197-205. PubMed ID: 26033545
    [Abstract] [Full Text] [Related]

  • 11. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.
    Oncotarget; 2015 Oct 06; 6(30):30295-305. PubMed ID: 26210286
    [Abstract] [Full Text] [Related]

  • 12. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 13. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM, Alvi MA, Bydon M, Quinones-Hinojosa A, Chaichana KL.
    Clin Neurol Neurosurg; 2019 Jul 10; 182():32-36. PubMed ID: 31063969
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
    Qiu X, Chen Y, Bao Z, Chen L, Jiang T.
    Radiother Oncol; 2022 Feb 10; 167():1-6. PubMed ID: 34902368
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection.
    Wu J, Kim C, Bai HX, Tang L, Wang Y, Li X, Zhang Z, Karakousis G, Huang R, Zhang PJ, Xiao B, Yang L.
    World Neurosurg; 2019 Feb 10; 122():e108-e120. PubMed ID: 30261385
    [Abstract] [Full Text] [Related]

  • 18. Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.
    Liu Y, Liu S, Li G, Li Y, Chen L, Feng J, Yang Y, Jiang T, Qiu X.
    Cancer; 2022 Mar 01; 128(5):1085-1092. PubMed ID: 34780673
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H, Vallières M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, Zhou J, Zhang P, Yang L.
    Neuro Oncol; 2017 Jun 01; 19(6):862-870. PubMed ID: 28339588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.